IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 360 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $26,227,969 | -19.1% | 578,218 | -26.8% | 0.01% | -16.7% |
Q2 2023 | $32,425,106 | +359.3% | 790,278 | +300.1% | 0.01% | +500.0% |
Q1 2023 | $7,059,472 | -58.8% | 197,523 | -56.5% | 0.00% | -66.7% |
Q4 2022 | $17,149,317 | -20.8% | 454,046 | -7.2% | 0.00% | -40.0% |
Q3 2022 | $21,653,000 | +6.1% | 489,532 | -11.2% | 0.01% | 0.0% |
Q2 2022 | $20,411,000 | -57.9% | 551,343 | -57.9% | 0.01% | -50.0% |
Q1 2022 | $48,472,000 | +19.1% | 1,308,624 | -2.2% | 0.01% | +25.0% |
Q4 2021 | $40,703,000 | +3.9% | 1,337,571 | +14.5% | 0.01% | +14.3% |
Q3 2021 | $39,171,000 | +35.1% | 1,167,857 | +60.7% | 0.01% | 0.0% |
Q2 2021 | $28,992,000 | +73.2% | 726,780 | +95.2% | 0.01% | +75.0% |
Q1 2021 | $16,736,000 | -62.9% | 372,249 | -53.3% | 0.00% | -66.7% |
Q4 2020 | $45,085,000 | -54.0% | 797,390 | -61.4% | 0.01% | -57.1% |
Q3 2020 | $97,927,000 | +22.8% | 2,063,813 | +52.6% | 0.03% | -3.4% |
Q2 2020 | $79,757,000 | -8.6% | 1,352,725 | -26.7% | 0.03% | -25.6% |
Q1 2020 | $87,230,000 | +145.3% | 1,844,992 | +213.5% | 0.04% | +160.0% |
Q4 2019 | $35,557,000 | +193.3% | 588,597 | +190.8% | 0.02% | +200.0% |
Q3 2019 | $12,125,000 | -75.9% | 202,380 | -74.1% | 0.01% | -77.3% |
Q2 2019 | $50,229,000 | +107.2% | 781,529 | +161.7% | 0.02% | +83.3% |
Q1 2019 | $24,243,000 | +75.4% | 298,679 | +16.8% | 0.01% | +50.0% |
Q4 2018 | $13,821,000 | -31.1% | 255,654 | -34.2% | 0.01% | -11.1% |
Q3 2018 | $20,047,000 | +127.3% | 388,663 | +83.6% | 0.01% | +125.0% |
Q2 2018 | $8,820,000 | -59.5% | 211,666 | -57.2% | 0.00% | -63.6% |
Q1 2018 | $21,777,000 | +60.1% | 494,053 | +82.7% | 0.01% | +37.5% |
Q4 2017 | $13,599,000 | +79.7% | 270,358 | +81.1% | 0.01% | +33.3% |
Q3 2017 | $7,569,000 | -32.6% | 149,300 | -32.3% | 0.01% | -33.3% |
Q2 2017 | $11,223,000 | +19.0% | 220,628 | -5.9% | 0.01% | +12.5% |
Q1 2017 | $9,430,000 | +12.6% | 234,569 | +34.0% | 0.01% | 0.0% |
Q4 2016 | $8,375,000 | -56.7% | 175,105 | -66.8% | 0.01% | -60.0% |
Q3 2016 | $19,322,000 | +148.2% | 527,363 | +174.4% | 0.02% | +100.0% |
Q1 2016 | $7,785,000 | – | 192,216 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |